JNCI-Journal of the National Cancer Institute

Article	Citations
Correction to: TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer	319
Correction to: RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study	209
Correction to: ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications	168
Corrigendum to: Receptivity to a Nurse-Led Symptom Management Intervention among Highly Symptomatic Patients with Cance	165
Corrigendum to: Realizing the Promise of Personalized Colorectal Cancer Screening in Practice	121
BRCA1/2 germline sequencing in children and adolescents with cancer: it is the context that matters	119
Retraction and Replacement of: Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening	115
Surgical Care for Older Adults: The Importance of Patient-Centered Outcomes in Daily Practice	114
The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045	114
Publisher’s Note	104
Reviewers	100
Correction to: RE: Grade Migration of Prostate Cancer in the United States During the Last Decade	99
Response to Liu, Xiao, Liu, et al.	99
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial	98
Response to Liu and Zhang	84
Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort	76
Colon, colorectal and all cancer incidence increase in the Young due to appendix reclassification	72
Editor’s Note to: Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex	69
RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study	61
Stat Bite: Estimated cumulative risk of female breast cancer incidence and mortality (ages 0-74) in 2022	61
Addressing Diversity, Equity, and Inclusion at the JNCI Journals	60
Cancer Hazard Evaluations for Contemporary Needs: Highlights From New National Toxicology Program Evaluations and Methodological Advancements	59
Adverse birth outcomes of adolescent and young adult women diagnosed with cancer during pregnancy	56
Addressing Social Determinants of Health: Now Is the Time	56
Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions	55

Response to Maltoni, Puccetti, Poli, et al.	54
Mediators of Racial Disparities in Heart Dose Among Whole Breast Radiotherapy Patients	54
Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials	51
Inflammatory and insulinemic dietary patterns and risk of endometrial cancer among US women	51
New and Persistent Sedative-Hypnotic Use After Adjuvant Chemotherapy for Breast Cancer	49
Childhood body mass index trajectories, adult-onset type 2 diabetes, and obesity-related cancers	47
Augmenting randomized clinical trial data with historical control data: Precision medicine applications	47
Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019	46
Combined individual participant data: highest-level evidence on obesity and colorectal cancer molecular subtypes	45
Body mass index and molecular subtypes of colorectal cancer	45
Mass incarceration and cancer health disparities in the United States: reimagining models of care delivery	43
Effect of chronic disease on racial difference in COVID-19–associated hospitalization among cancer patients	43
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study	41
Human papillomavirus–associated anal squamous cell carcinoma: sociodemographic, geographic, and county-level economic trends in incidence rates—United States, 2001-2019	41
Leadership Diversity and Development in the Nation’s Cancer Centers	40
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C	40
Mental health outcomes in a population-based cohort of patients with prostate cancer	40
Assessment of Caregivers’ Burden When Caring for Patients With Pancreatic and Periampullary Cancer	40
Validating a model for predicting breast cancer and nonbreast cancer death in women aged 55 years and older	40
Recommendations for Epstein-Barr virus–based screening for nasopharyngeal cancer in high- and intermediate-risk regions	39
Vertical integration in oncology: what does it mean for patients with cancer?	38
RE: Use of artificial intelligence for cancer clinical trial enrollment	37
Evaluating the sensitivity of EQ-5D-5L in patients with brain metastases: a secondary analysis of NRG CC001	37
Long-term aspirin use and cancer risk: a 20-year cohort study	37
Bilaterality, not multifocality, is an independent risk factor for recurrence in low-risk papillary thyroid cancer	37
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355	36
Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients?	36
Simulating the population impact of interventions to reduce racial gaps in breast cancer treatment	36
Housing Insecurity Among Patients With Cancer	36
Addressing health-related quality of life inequities in cancer: where do we go from here?	36
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations	35
Cancer mortality rates by racial and ethnic groups in the United States, 2018-2020	35
Can time to deterioration in patient-reported outcomes be a surrogate for overall survival?	34
Re: Deng and Heybati	34
Low physical function following cancer diagnosis is associated with higher mortality risk in postmenopausal women	34
NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer	32
Response to Sorscher	32
Advancing rapid cycle research in cancer care delivery: a National Cancer Institute workshop report	32
Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants	32
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival	32
Method of primary breast cancer detection and the disease-free interval, adjusting for lead time	32
RE: Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers	31
Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study	31
Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study	31
RE: The impact of multidisciplinary cancer conferences on overall survival: a meta-analysis	30
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402	30
COVID-19 vaccination, infection, and symptoms among cancer survivors in the United States	30
Prevalence of anal cytology screening among persons with HIV and lack of access to high-resolution anoscopy at HIV care facilities	30
Geriatric assessment and management: is decreasing treatment toxicity good enough?	30
Dyslipidemia and cardiovascular disease among childhood cancer survivors: a St. Jude Lifetime Cohort report	30

Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: an international, multi-institutional, real-world study	29
Response to Wu and Zhang	29
RET overexpression leads to increased brain metastatic competency in luminal breast cancer	29
The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor–Positive Breast Cancer	28
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment	28
Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405	28
Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience	28
Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer	27
Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy	26
The National Cancer Institute Funding of Global Research: Lessons Learned and Opportunities Going Forward	26
Reducing ovarian cancer mortality through screening: an impossible dream?	26
Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia	26
Evaluating a blood test for colon cancer screening: how simulation modeling can inform clinical policy making and research	26
Health insurance among survivors of childhood cancer following Affordable Care Act implementation	26
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics	26
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab	25
Response to Khouri and Suissa	25
ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications	25
Racial and socioeconomic disparities in non–small cell lung cancer molecular diagnostics uptake	24
Cancers with epidemiologic signatures of viral oncogenicity among immunocompromised populations in the United States	24
Comparing the efficacy and safety of first-line treatments for chronic lymphocytic leukemia: a network meta-analysis	24
Response to Huang, Rivero-Hinojosa, Ma, et al	24
Association of immunoglobulin E levels with glioma risk and survival	24
BRCA1/2 and Endometrial Cancer Risk: Implications for Management	24
Untangling the Relationship Between Clonal Hematopoiesis and Ovarian Cancer Therapies	24
Cancer Mortality in Latino Populations by Birthplace and Generation: A Complex Analysis	24
Adherence to National Guidelines on Cervical Screening: A Population-Based Evaluation From a Statewide Registry	24
Obstetrical and Perinatal Outcomes in Female Survivors of Childhood and Adolescent Cancer: A Population-Based Cohort Study	23
Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a US cohort	23
Medication–Associated Phthalate Exposure and Childhood Cancer Incidence	23
Uptake of breast cancer screening practices in low- and middle-income countries: a systematic review and meta-analysis	23
Disparities in Risk of Advanced-Stage Liver Cancer and Mortality by Race and Ethnicity	23
Disparities in the availability of and access to neuro-oncology trial-supporting infrastructure in the United States	23
The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17	22
Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminoma	22
Medical Financial Hardship in Survivors of Adolescent and Young Adult Cancer in the United States	22
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation	21
Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis	21
When the somatic genome informs the germline: the example of TP53	21
A new perspective on mitigating lung cancer risks through smoking cessation and reduction	21
Risk factors for breast cancer subtypes by race and ethnicity: a scoping review	21
Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules	21
Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020	21
Age Is Just a Number: Considerations for Older Adults in Cancer Clinical Trials	21
The risk and benefit profiles of US-eligible lung cancer screening attendees vs nonattendees	20
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial	20
Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO)	20
The impact of multidisciplinary cancer conferences on overall survival: a meta-analysis	20
Modeling disparities in colorectal cancer outcomes: colonoscopy follow-up and quality are key	20
Long-term survival across Breslow thickness categories: findings from a population-based study of 210 042 Australian melanoma patients	19
Survivorship after adolescent and young adult cancer: models of care, disparities, and opportunities	19
Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B–Southwest Oncology Group 80702 (Alliance)	19
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer	19
Deciphering the sex gap in global life expectancy: the impact of female-specific cancers 1990-2019	19
RE: Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group	19
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130	18
Li-Fraumeni Syndrome in the Cancer Genomics Era	18
Assessment of intermediate-term mortality following pancreatectomy for cancer	18
Real-World HPV Vaccine Effectiveness Studies: Guideposts for Interpretation of Current and Future Studies	18
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer	18
Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis	18
Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model	18
Genotypic vs Phenotypic Risk Assessment for Melanoma	17
Evaluating clinical utility of comprehensive genomic profiling—challenges and opportunities	17
Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline	17
Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer	17
Body Mass Index and Risk of Second Cancer Among Women With Breast Cancer	17
Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data	17
Cancer Surveillance Opportunities to Meet Prevention and Control Challenges	17
Response to Krieger	16
Physical activity, metabolites, and breast cancer associations	16
The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis	16
Lower survival for surgical treatment of human papillomavirus–related oropharynx cancer at community cancer centers	16
Understanding risk factors for endometrial cancer in young women	16
Evidence Gaps in Cancer Survivorship Care: A Report From the 2019 National Cancer Institute Cancer Survivorship Workshop	16
Assessing the effect of the COVID-19 pandemic on 1-year cancer survival in the United States	16
Cancer’s Lasting Financial Burden: Evidence From a Longitudinal Assessment	16
RE: Association of metformin use and cancer incidence: a systematic review and meta-analysis	16
Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer	16
Response to Klar and Adams	16

The association of where patients with prostate cancer live and receive care on racial treatment inequities	15
Trends in breast cancer–specific death by clinical stage at diagnoses between 2000 and 2017	15
Gauging the efficacy of multicancer screening: the road ahead may be long and bumpy	15
Risk factors for second primary breast cancer by laterality, age, and race and ethnicity	15
Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer	15
COVID-19 Vaccine Among Actively-Treated People With Cancer: A Glimpse Into the Known Unknowns?	15
Banning Menthol Cigarettes: The Time Has Come	15
World Trade Center Rescue and Recovery Workers: Cancer Increases Are Beginning to Emerge	15
The Development of Global Cancer Research at the United States National Cancer Institute	15
Benefit vs Harm of Internal Mammary Node Irradiation for Node-Positive Breast Cancer	15
Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial	14
Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology	14
Clinical Benefit Scales and Trial Design: Some Statistical Issues	14
The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer	14
Factors associated with timely COVID-19 vaccination in a population-based cohort of patients with cancer	14
Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds	14
Supporting evidence in phase 2 cancer trial protocols: a content analysis	14
Genomic Determinants of Early Recurrences in Low-Stage, Low-Grade Endometrioid Endometrial Carcinoma	14
Do Cell Phones Cause Brain Tumors? Another Piece of the Puzzle	14
Rural–Urban Disparities in Cancer Outcomes: Opportunities for Future Research	14
The Unrelenting Impact of Poverty on Cancer: Structural Inequities Call for Research and Solutions on Structural Determinants	14
Correction to: Longitudinal e-Cigarette and Cigarette Use Among US Youth in the PATH Study (2013–2015)	14
Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older	14
Effect of chemotherapy and surgery timing on mortality in upper and lower extremity osteosarcoma	14
The long economic shadow of a cancer diagnosis during adolescence or young adulthood	14
Another Weak Link in the Electron Transport Chain: Variants in SUCLG2 and Risk for Pheochromocytoma and Paraganglioma	14
Obligate and Potential Precursors of Melanoma	14
The evolution of NCI’s Health Information National Trends Survey: methods, data, and future directions	13
Editor’s Note on: Structural Basis for Depletion of Heat Shock Protein 90 Client Proteins by Deguelin	13
Correction to: Quality of Life in Older Adults After Major Cancer Surgery: The GOSAFE International Study	13
Clinical and patient-reported outcomes after oncoplastic vs conventional breast-conserving surgery—a longitudinal, multicenter cohort study	13
Making the case for an International Childhood Cancer Data Partnership	13
Correction to: Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer	13
Corrigendum to: Master protocol trial design for efficient and rational evaluation of novel therapeutic oncology devices	13
Correction to: Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome	13
Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers	13
RE: Glucagon-like peptide 1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data	13
Corrigendum to: p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women	13
Effects of high-fiber, high-fruit and high-vegetable, low-fat dietary intervention on the rectal tissue microbiome	13
Disparities in cervical cancer elimination time frames in the United States: a comparative modeling study	13
Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers	13
Evaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK Biobank	13
Development of a policy model for pediatric acute lymphoblastic leukemia to facilitate economic evaluation	12
Response to Lehrer and Rheinstein and to Alexiou, Zagorianakou, and Voulgaris	12
Vitamin D receptor gene polymorphisms, bioavailable 25-hydroxyvitamin D, and hepatocellular carcinoma survival	12
Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer	12
Epidemiology of early vs late recurrence among women with early stage estrogen receptor–positive breast cancer in the Pathways Study	12
RE: Autoimmune disease and the risk of anal cancer in the US elderly population	12
Temporal trends of subsequent central nervous system malignancies among survivors of childhood cancer	12
Correction to: Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules	12
Correction to: Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial	12
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line col	12
Frailty and outcomes in adults undergoing systemic anti-cancer treatment: a systematic review and meta-analysis	12
Targeted eHealth Intervention to Reduce Breast Cancer Survivors’ Fear of Recurrence: Results From the FoRtitude Randomized Trial	12
Time-restricted eating and cancer: lessons learned and considerations for a path forward	12
RE: Enhancing capacity for primary care research in cancer survivorship: National Cancer Institute Meeting Report	12
Response to Oleribe	12
Probing the relevance of BRCA1 and BRCA2 germline pathogenic variants beyond breast and ovarian cancer	12
NCCN guideline–concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers	12
Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspective	12
Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy	11
An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals	11
An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer	11
Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis	11
Changes in Mammography Use by Women’s Characteristics During the First 5 Months of the COVID-19 Pandemic	11
Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density	11
Does Artificial Intelligence Meaningfully Enhance Cystoscopy?	11
Executing plans to enhance diversity across cancer centers in the United States: opportunities and challenges	11
A national evaluation of adjuvant chemotherapy in pT4N0M0 colon cancer from the National Cancer Database	11
Essentialism and Exclusion: Racism in Cancer Risk Prediction Models	11
Impact of knowledge of human papillomavirus positivity on cervical cytology performance in Latin America	11
Workforce Caring for Cancer Survivors in the United States: Estimates and Projections of Use	10
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients	10
Response to Zhang and Yang	10
Proinflammatory dietary pattern and risk of total and subtypes of breast cancer among US women	10
Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials	10
Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer	10
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1–Negative Lung Adenocarcinomas	10
Identification of Mitochondrial DNA Variants Associated With Risk of Neuroblastoma	10
Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men	10
RE: Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients	10
Oral Contraceptives and BRCA Cancer: A Balancing Act	10
Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study	10
Smoking and Incidence of Colorectal Cancer Subclassified by Tumor-Associated Macrophage Infiltrates	10
The state of cancer-focused community outreach and engagement (COE): reflections of Black COE directors	10
RE: Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study	9
Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care	9
Association of Genetic Ancestry With Terminal Duct Lobular Unit Involution Among Healthy Women	9
Optimizing public-private partnerships to support clinical cancer research	9
RE: Prevalence of cancer survivors in the United States	9
Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective	9
Response to Wernly, Datz, and Wernly	9
RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis	9
Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia	9
Association Between Medicaid Expansion Under the Affordable Care Act and Survival Among Newly Diagnosed Cancer Patients	9